Study to monitor and treat sinus problems in wet AMD
Part of Cancer clinical trials.
This study looks at whether sinus infections or inflammation affect people who have “wet” age-related macular degeneration and are already receiving regular eye injections. It may help them find better ways to detect and manage sinusitis while continuing AMD care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been followed and treated for wet AMD in both eyes for at least 2 years
- In the year before joining, you had at least 6 eye injections in at least one eye
- You can sign consent to join, and you have a French social security plan
- You should not already be receiving treatment for sinusitis (acute or ongoing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This study tests new ways to diagnose glaucoma (and sometimes related eye conditions) using eye exams and measurements. It may help improve how doctors detect glaucoma earlier and more accurately.
Hear when a new AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.